ESC 365 - Thromboembolic prevention after TAVI: antiplatelets or anticoagulants? - Conclusion

ESC Premium Access

Thromboembolic prevention after TAVI: antiplatelets or anticoagulants? - Conclusion

Session: Thromboembolic prevention after TAVI: antiplatelets or anticoagulants?

Topic: Non coronary cardiac interventions

Speaker: Professor S. Windecker (Bern, CH)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Stephan Windecker

Bern University Hospital, Inselspital, Bern (Switzerland)

43 presentations

9 followers

4 more presentations in this session

Thromboembolic prevention after TAVI: antiplatelets or anticoagulants? Positioning of the topic

Speaker: Professor R. Mehran (New York, US)

All we need are antiplatelet agents – PRO

Speaker: Doctor A. Colombo (Milan, IT)

All we need are antiplatelet agents – CON

Speaker: Professor L. Sondergaard (Copenhagen, DK)

All we need are antiplatelet agents – Discussion PRO/CONTRA.

Access the full session

Thromboembolic prevention after TAVI: antiplatelets or anticoagulants?

Speakers: Professor S. Windecker, Professor R. Mehran, Doctor A. Colombo, Professor L. Sondergaard

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources